New diabetes clinical trial: Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Published on: January 02, 2024 at 11:00PM
Conditions: Diabetic Foot Ulcers
Interventions: Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo
Sponsors: Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.; Parexel
Not yet recruiting
https://ift.tt/yLdXb5P